Article, see p 2592 T he adult human heart is a fascinating organ. Despite weighing no more than 300 g (on average), it pumps 8 tons of blood through 60 000 miles of blood vessels each day. This remarkable performance is energetically demanding and consumes ≤10% of the body's energy. However, the heart has little capacity for energy storage and thus relies on the continuous supply of exogenous metabolic resources.
The Notch pathway functions as a key intercellular communication mechanism that controls many developmental and homeostatic processes. 5 It is activated by ligands such as Delta-like 4 (DLL4), which induce the proteolytic cleavage of Notch receptors in adjacent cells to release the so-called Notch intracellular domain. This activated receptor fragment migrates to the nucleus, where it interacts with the DNA-binding protein RBPJ and the coactivator MAML1 to drive the expression of Notch target genes (Figure, B) . In the vascular endothelium, Notch signaling coordinates several critical steps of blood vessel morphogenesis and is generally thought to restrict vascular expansion. 6, 7 Signaling through this pathway has also been implicated in the maintenance of endothelial quiescence, 8 yet its role in the adult (quiescent) vasculature is not well defined.
Jabs and colleagues 3 began to address this question by analyzing the tissue expression profile of NOTCH1-the main Notch receptor in endothelial cells. They observed that Notch signaling was particularly active in the endothelium of © 2018 American Heart Association, Inc.
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The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. the mouse heart, signified by the abundance of the NOTCH1 intracellular domain in these cells. On the basis of this finding, they asked whether endothelial Notch signaling might have a role in cardiac homeostasis and inhibited Notch-mediated signal transduction with a DLL4-neutralizing antibody. It is interesting to note that some antibody-treated mice developed ventricular dysfunction, similar to human patients with cancer who received DLL4-blocking antibodies in phase I oncology trials. 9, 10 Because the antibody might also disrupt Notch activity in other cell types of the heart, the authors used mouse genetics and inactivated the RBPJ gene specifically in endothelial cells of adult mice. Loss of this canonical Notch effector also led to impaired cardiac function. RBPJ mutants developed profound myocardial hypertrophy, and cardiomyocytes had enlarged mitochondria and reduced ATP levels. The hypertrophic cardiomyocytes reactivated a fetal gene expression program that is associated with heart failure, in which glucose metabolism genes are activated and genes related to fatty acid oxidation are suppressed. As a result of all these changes, cardiac ejection fraction was severely compromised, and endothelial-specific RBPJ mutant mice eventually succumbed to heart failure.
In search for an underlying mechanism, Jabs and colleagues 3 analyzed the heart vasculature in the RBPJ mutant mice. During development and in growing tumors, inhibition of endothelial Notch activity has been shown to promote the formation of a hypersprouted, nonfunctional vascular network that impedes tissue perfusion. 6 Deletion of RBPJ in the adult setting also increased vessel density in the myocardium, consistent with the established role of the Notch pathway in limiting angiogenic responses. However, they found no evidence for myocardial hypoxia or altered tissue perfusion, which suggested that the overt heart failure phenotype has alternative causes. The authors concluded that, besides its well-known role in suppressing vascular growth, Notch signaling controls additional functions in cardiac endothelial cells.
The researchers noted that endothelial Notch inhibition also led to alterations in lipid metabolism evident by an accumulation of fatty acids in plasma and liver. However, it is striking that the animals' body fat was normal and hepatic lipid metabolism was unaffected, which led to the assumption that delivery to fatty acidconsuming tissues was impaired. Indeed, they observed that fatty acid transfer to muscle cells was diminished in the RBPJ mutant mice, which correlated with a reduced ability of endothelial cells to take up long-chain fatty acids upon Notch inhibition. To gain further mechanistic insight, the authors analyzed the expression levels of genes involved in transendothelial fatty acid transport. They found that endothelial Notch signaling controls the expression of endothelial lipase and angiopoietin-like 4 to facilitate vascular lipolysis and fatty acid translocase and fatty acid-binding protein 4 to promote transcellular transport. Inhibition of these gene expression changes likely contributed to impaired fatty acid shuttling in the RBPJ knockout mice, thus forcing cardiomyocytes to switch from fatty acid to glucose metabolism. Indeed, Jabs et al 3 observed increased glucose uptake and catabolism as well as activation of prohypertrophic kinases, including mTOR, potentially inducing cardiac hypertrophy and ensuing heart failure. Moreover, they showed that survival of the RBPJ mutant mice could be prolonged by treatment with the mTOR inhibitor rapamycin or by administration of a ketogenic diet to enforce a switch from glucose to alternative noncarbohydrate usage. Altogether these data provide compelling evidence for a central role of Notch signaling in the coordination of nutrient transport processes in the heart.
The regulation of endothelial fatty acid transfer by the Notch pathway may seem unusual at first glance. However, given its importance for establishing mature, fully functional vascular networks, it is plausible that Notch activity optimizes nutrient delivery in an organ that depends on an efficient metabolic supply. Thus, the work of Jabs and colleagues 3 identifies DLL4/NOTCH1 signaling as a mechanism that links quiescence and functional specialization of cardiac endothelial cells to ensure homeostasis in the heart (Figure, B) . However, as with many new studies, it raises many questions. For example, how does a relatively simple pathway such as Notch, which is widely used in the cardiovascular system, exert tissue-restricted effects? Does Notch regulate nutrient transport in conjunction with the transcription factors MEOX2/ TCF15, which have been demonstrated to control fatty acid transfer in the heart? 11 Or is endothelial Notch activity refined by cues from the cardiac microenvironment (eg, by signals from the myocardium)? An example for such a cardiomyocyte-derived signal could be the vascular endothelial growth factor B, which has been suggested by some studies 12 (but not all 13 ) to facilitate endothelial fatty acid uptake. Another important question to address is whether Notch influences the metabolism of cardiac endothelial cells. Endothelial metabolism is a critical determinant of vascular growth and function, 14 and an increased ingestion of fatty acids could also fuel fatty acid catabolism. Because endothelial cells rely on glucose when they sprout, migrate, and proliferate, 15 an altered substrate supply (and usage) might affect their activity and thereby contribute to the maintenance of quiescence in the cardiac endothelium.
Looking at the broad picture, the investigations by Jabs et al 3 highlight the need to understand endothelial transport processes in greater detail. An insufficient or aberrant supply of nutrients, metabolites, or signaling molecules may instigate or perpetuate tissue dysfunction in various other diseases. Therefore, future studies in this direction should use more selective manipulations of endothelial transport processes, rather than blocking Notch signaling, and should include additional vascular beds and pathological stresses. Identifying the signals and molecules that maintain, adapt, or disrupt endothelial transport capacity could be important clinically and may offer new targets for the treatment of a wide range of cardiovascular disorders, including heart failure.
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